USP19 and pulmonary arterial hypertension: Next, we used the DUB inhibitor PR-619 and a previously validated sgRNA against USP19 from our CRISPR-based DUB knockout library27 to transiently knock down USP19 levels, and analyzed the ubiquitination status of PAH.